<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151630</url>
  </required_header>
  <id_info>
    <org_study_id>393219</org_study_id>
    <nct_id>NCT02151630</nct_id>
  </id_info>
  <brief_title>Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts</brief_title>
  <official_title>Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plantar warts can be bothersome and painful requiring treatment. The investigators will
      compare the efficacy of pyruvic acid and salicylic acid in treating multiple plantar warts.
      Patients with multiple plantar warts will be randomized to receive either pyruvic acid 70%
      or compound salicylic acid solution (salicylic acid 16.7%, lactic acid 16.7%, and collodion
      100%) applying topically twice a day for 4 weeks. Patients will be visited every 2 weeks for
      one month after starting treatment and then every one month for up to 3 months. The number
      and size of warts will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Wart number</measure>
    <time_frame>From before to 3 months after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be visited every two weeks for one month and then every month for up to 3 months by a dermatologist. On each visit, warts will be inspected to determine the number of warts. Any wart totally non-detectable by inspection and touch will be considered as healed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wart size</measure>
    <time_frame>From before to 3 months after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be visited every two weeks for one month and then every month for up to 3 months by a dermatologist. On each visit, warts will be inspected to determine the size of warts. The size of the warts will be calculated as the mean size of all the warts.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Plantar Wart</condition>
  <arm_group>
    <arm_group_label>Pyruvic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salicylic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyruvic acid</intervention_name>
    <arm_group_label>Pyruvic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salicylic Acid</intervention_name>
    <arm_group_label>Salicylic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 12 years and above

          -  multiple warts (at least 2)

        Exclusion Criteria:

          -  mosaic warts

          -  already under any treatment for warts

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatima Assaf, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatima Assaf, M.D.</last_name>
    <phone>0098 913 0965384</phone>
    <email>dr.assafsaid@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Diseases and Leishmaniasis Research Center</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima Assaf, M.D.</last_name>
      <phone>0098 913 0965384</phone>
      <email>dr.assafsaid@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fatima Assaf, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011 Aug;165(2):233-46. doi: 10.1111/j.1365-2133.2011.10218.x. Epub 2011 May 26. Review.</citation>
    <PMID>21219294</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Fatima Assaf</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>wart</keyword>
  <keyword>verruca vulgaris</keyword>
  <keyword>topical therapy</keyword>
  <keyword>pyruvic acid</keyword>
  <keyword>salicylic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Foot Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Salicylic Acid</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
